Titel

Stopping ACE-inhibitors in COVID-19

Kurzzusammenfassung

The COVID-19 pandemic currently poses unprecedented challenges to the health systems of all countries. Experimental studies show that the SARS-CoV2 virus enters human cells via the angiotensin converting enzyme II receptor 2 (ACE2). ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB) can lead to an increase in the expression of ACE2. Therefore, there is concern that in patients treated with ACEI or ARB, the absorption of the virus is facilitated, thereby accelerating its spread in the body. ACEI-COVID tests the hypothesis that stopping chronic ACEI / ARB therapy in SARS-CoV2-infected patients improves outcomes.

Zentren/Kontakt:

LMU Klinikum, München: Dr. Steffen Massberg, Tel. 08944007, Email: steffen.massberg@med.uni-muenchen.de

Asklepios Stadtklinik Bad Tölz: Dr. Ulrich Kreider-Stempfle

Klinikum Landkreis Erding: Dr. Lorenz Bott-Flügerl

Klinikum Memmingen: Dr. Andreas May

Deutsches Herzzentrum München: Dr. Heribert Schunkert

Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, München: Dr. Karl-Ludwig Laugwitz

München Klinik Bogenhausen und Schwabing: Dr. Florian Straube

Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg: Dr. Mathias Pauschinger

Klinikum Starnberg: Dr. Peter Trenkwalder

Klinik für Innere Medizin Weilheim: Andreas Knez

Details

 

Stand: 05.05.2020, Quelle: www.clinicaltrials.gov

Menü